Arrowhead Research Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline.
... "today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate" ...
The good thing that the company prepare thier papers to send it to FDA ..
"We anticipate filing an IND in Q2 of 2013 and our plan is to conduct a phase 1 clinical trial in chronic HBV carriers to provide early proof of concept."
http://www.marketwatch.com/story/arrowhead-research-advances-arc-520-into-ind-enabling-studies-for-the-treatment-of-hepatitis-b-and-provides-guidance-on-development-timeline-2012-06-06